The San Francisco Cancer Summit
Biocom Bay Area

Luke Timmerman Seattle Cancer Summit 

We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment — these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to the Kilimanjaro Climb to Fight Cancer, a philanthropic campaign to support basic science research at Fred Hutch.

Confirmed speakers:

  • Hal Barron, chief scientific officer and president of R&D, GlaxoSmithKline
  • David Chang, co-founder and CEO, Allogene Therapeutics
  • Carolyn Bertozzi, Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and Co-Founder, Palleon Pharmaceuticals
  • Ira Mellman, vice president, research oncology, Genentech
  • Harlan Robins, member, Fred Hutch; program head, computational biology; co-founder, Adaptive Biotechnologies
  • Stanley Riddell, member, Fred Hutch; scientific director, Immunotherapy Integrated Research Center; co-founder, Juno Therapeutics
  • Bonnie Anderson, co-founder and CEO, Veracyte
  • Nina Kjellson, general partner, Canaan Partners*
  • Kristina Burow, managing director, ARCH Venture Partners 
  • Ben Hindson, co-founder and CSO, 10X Genomics
  • Larry Corey, past president of Fred Hutch, co-PI of the HIV Vaccine Trials Network
  • Lesley Stolz, head, JLABS Bay Area*
  • Bill Newell, CEO, Sutro Biopharma*
  • Omid Farokhzad, CEO, Seer
  • Angie You, CEO, Amunix Pharmaceuticals
  • Steve James, CEO, Pionyr Immunotherapeutics
  • Bassil Dahiyat, CEO, Xencor
  • Luke Timmerman, founder and editor, Timmerman Report*
  • Kristen Hege, VP of translational development, hematology/oncology, Celgene
  • Amy DuRoss, CEO, Vineti
  • Ken Brunt, VP of customer operations, Veracyte*
  • Kevin Conroy, CEO,  Exact Sciences
  • Daniel Corey, co-founder, Cero Therapeutics
  • Bob More, partner, Alta Partners
  • Racquel Bracken, vice president, Venrock
  • Julia Owens, CEO, Millendo Therapeutics


  • Veracyte
  • Alexandria Real Estate Equities 
  • Takeda Pharmaceuticals
  • Foundation Medicine
  • Madryn Asset Management
  • Johnson & Johnson Innovation, JLABS
  • Biocom

*Denotes Kilimanjaro climber

Time: 1:00 PM - 6:00 PM
1 Tower Place
South San Francisco, CA 94080

If you'd like to attend this event you can purchase tickets online.

(ticket purchase required)
(ticket purchase required)

Return to Calendar